All In Biotech

Drug Trial Radar · NCT07201922

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Feb 10, 2026

Primary completion

May 14, 2029

Study completion May 23, 2029

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Oct 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe. People can join if a lung scan shows early changes in the lung, called interstitial lung abnormalities, which may lead to lung scarring. People with family members who have pulmonary fibrosis are more likely to develop it themselves. That is why it is important to check early for lung changes and find ways to prevent the condition from getting worse. The purpose of this study is to find out whether a medicine called nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis. Participants are put into one of 2 groups randomly, which means the group is chosen by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet twice a day for about 2 to 3 years. There is a 3 out of 5 chance that participants will receive nerandomilast instead of the placebo. Participants are in the study for about 2 to 3 years. Participants visit the study site multiple times: more frequently during the first 2 years (about every 3 months), and then every 6 months thereafter. In the 3rd year, participants also have phone calls with the site staff every 3 months. Doctors regularly test lung function and take chest scans to see if the treatment works. The results are compared between the 2 groups to see if nerandomilast helps. The doctors also check participants' health and take note of any unwanted effects.

Conditions

  • Familial Pulmonary Fibrosis
  • Interstitial Lung Abnormalities
  • Interstitial Lung Diseases

Interventions

  • NerandomilastDrug

    Nerandomilast

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to physiologic or radiologic worsening of ILA/ILD over the whole trialTime frame: up to 164 weeks

Locations

55 sites in 13 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California · Not yet recruiting

  • University of Colorado Denver

    Aurora, Colorado · Recruiting

  • Clinical Research Specialists LLC - Kissimmee

    Kissimmee, Florida · Recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Weill Cornell Medicine-New York-60569

    New York, New York · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

  • Centro de Investigaciones Metabolicas (CINME)

    Buenos Aires, Argentina · Recruiting

  • Hospital Italiano de Buenos Aires

    CABA, Argentina · Recruiting

  • Fundacion NIBA Neurologia Infantil Buenos Aires

    CABA, Argentina · Recruiting

  • Centro de Investigacion Clinica Belgrano

    CABA, Argentina · Recruiting

  • Consultorios Medicos del Buen Ayre

    Capital Federal, Argentina · Recruiting

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia · Recruiting

  • Lung Research Queensland

    Chermside, Queensland, Australia · Recruiting

  • The Prince Charles Hospital

    Chermside, Queensland, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • St. Joseph's Healthcare Hamilton

    Hamilton, Ontario, Canada · Recruiting

  • McGill University Health Centre (MUHC)

    Montreal, Quebec, Canada · Recruiting

  • Hopital Louis Pradel

    Bron, France · Recruiting

  • INS Coeur Poumon

    Lille, France · Recruiting

  • HOP Bichat

    Paris, France · Recruiting

  • HOP Pontchaillou

    Rennes, France · Recruiting

  • Hôpital Larrey - CHU de Toulouse

    Toulouse, France · Recruiting

  • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH

    Essen, Germany · Recruiting

  • Medizinische Hochschule Hannover

    Hanover, Germany · Recruiting

  • Lungenfachklinik Immenhausen

    Immenhausen, Germany · Recruiting

  • Krankenhaus Bethanien gGmbH

    Solingen, Germany · Recruiting

  • IRCCS MultiMedica

    Milan, Italy · Recruiting

  • Azienda Ospedaliera Universitaria di Padova

    Padova, Italy · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy · Recruiting

  • Tosei General Hospital

    Aichi, Seto, Japan · Recruiting

  • Tsuboi Hospital

    Fukushima, Koriyama, Japan · Recruiting

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.